尔康制药(300267) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥426,347,681.19, representing an increase of 11.09% compared to the same period last year[3]. - The net profit attributable to shareholders decreased by 49.45% to ¥22,533,577.51, down from ¥53,028,821.97 in the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 59.71% to ¥16,440,304.31[3]. - Net profit for Q1 2022 was CNY 19,785,501.01, a decrease of 59.00% from CNY 48,397,485.29 in Q1 2021[20]. - The net profit attributable to the parent company was CNY 22,533,577.51, down 49.51% from CNY 44,572,950.98 in the previous year[20]. - Basic and diluted earnings per share for Q1 2022 were both CNY 0.0109, compared to CNY 0.0216 in Q1 2021[21]. - Other comprehensive income after tax for Q1 2022 was CNY -6,609,059.44, compared to CNY 13,995,956.56 in Q1 2021[20]. Cash Flow - The net cash flow from operating activities increased by 61.43% to ¥136,125,499.12, compared to ¥82,294,323.13 in the same period last year[3]. - The net cash flow from operating activities for Q1 2022 was ¥136,125,499.12, an increase of 61.5% compared to ¥84,323,093.26 in Q1 2021[23]. - Total cash inflow from investment activities was ¥215,492,136.98, significantly lower than ¥1,257,468,268.82 in the same period last year[23]. - The net cash flow from investment activities was -¥270,159,931.02, compared to -¥130,179,235.91 in Q1 2021, indicating a deeper cash outflow[23]. - Cash inflow from financing activities totaled ¥226,749,600.00, up from ¥200,000,000.00 in Q1 2021[24]. - The net cash flow from financing activities was ¥24,331,603.16, a decrease of 87.6% compared to ¥195,778,361.10 in the previous year[24]. - The ending balance of cash and cash equivalents was ¥490,328,338.90, down from ¥1,030,802,501.45 at the end of Q1 2021[24]. - The total cash outflow from operating activities was ¥455,524,810.67, compared to ¥333,694,758.21 in Q1 2021, reflecting a 36.5% increase[23]. - The company received tax refunds amounting to ¥11,994,861.31, compared to ¥5,542,048.67 in the previous year[23]. - The cash paid to employees was ¥57,968,689.28, an increase from ¥45,764,762.46 in Q1 2021[23]. - The impact of exchange rate changes on cash and cash equivalents was -¥1,539,578.01, compared to ¥589,162.18 in Q1 2021[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,462,015,211.26, a slight increase of 0.55% from the previous year[4]. - The company's current assets totaled CNY 1,998,820,428.78, compared to CNY 1,946,365,405.27 at the beginning of the year, reflecting an increase of approximately 2.5%[15]. - Cash and cash equivalents decreased to CNY 539,934,275.71 from CNY 761,564,289.06, representing a decline of about 29.1%[15]. - Inventory increased to CNY 768,324,073.23 from CNY 714,771,672.65, marking a rise of approximately 7.5%[15]. - Short-term borrowings rose to CNY 272,749,600.00 from CNY 246,000,000.00, indicating an increase of about 10.9%[16]. - The total liabilities as of March 31, 2022, were CNY 518,624,674.74, compared to CNY 498,926,461.51 at the beginning of the year, reflecting an increase of approximately 3.5%[16]. - Total liabilities as of the end of Q1 2022 were CNY 574,109,232.37, an increase from CNY 558,277,304.57 at the end of Q1 2021[20]. - Total equity attributable to shareholders of the parent company was CNY 4,869,042,013.17, slightly up from CNY 4,851,211,464.04 year-over-year[20]. Operational Challenges and Plans - The company's gross profit margin decreased due to logistics disruptions caused by the pandemic, affecting sales structure[4]. - The company plans to continue expanding its overseas pharmaceutical intermediate sales despite challenges in logistics[4]. - The company is facing delays in project commissioning due to the pandemic, affecting the installation and debugging of equipment for several projects[12]. - The company plans to invest CNY 18,040.25 million in a project in Cambodia to produce 10,000 tons of aniline, aimed at enhancing product lines and reducing production costs[12]. - A total of CNY 9,450 million is allocated for the construction of a project producing hydroquinone and other products, which is expected to improve product structure and create new profit growth points[12]. - The company has invested CNY 6,500 million in a project for adhesive production in Cambodia, which is intended to extend the existing industrial chain[13]. Cost and Expenses - Total operating costs for Q1 2022 were CNY 407,517,431.69, up 20.83% from CNY 337,035,488.15 in the same period last year[19]. - Research and development expenses for Q1 2022 were CNY 9,216,795.92, a decrease from CNY 9,876,478.73 in the same period last year[20]. - The company's financial expenses surged by 2,127.51% to ¥288.24, primarily due to increased exchange rate losses[8].